Purple Biotech Ltd (PPBT) FinancialsPPBTPurple Biotech Ltd

Evaluating the bottom line, Purple Biotech Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -122.82%, provide a clear picture of how effectively PPBT converts its operational activities into shareholder value.

In the context of the broader market, PPBT competes directly with industry leaders such as KYNB and ATNM. With a market capitalization of $2.81M, it holds a significant position in the sector. When comparing efficiency, PPBT's gross margin of N/A stands against KYNB's -81.45% and ATNM's 100.00%. Such benchmarking helps identify whether Purple Biotech Ltd is trading at a premium or discount relative to its financial performance.

The company reported a GAAP EPS of -$0.09 for Q1 2026, with an adjusted net loss of $2.1 million, reflecting ongoing challenges in profitability. However, it has a cash position of $6.4 million, which is expected to sustain operations into 2027, allowing for continued investment in R&D.